M. Kozloff

Treatment Patterns and Clinical Outcomes in Patients With Metastatic Colorectal Cancer Initially Treated with FOLFOX–Bevacizumab or FOLFIRI–Bevacizumab: Results From ARIES, a Bevacizumab Observational Cohort Study

Johanna C. Bendell, Tanios Bekaii‐Saab, Allen Lee Cohn et al. · The Oncologist · 2012 · 99 citations · Full text

Medicine, Oncology, Pharmacology +12

Association between exposure to bevacizumab (BV) beyond first progression (BBP) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Results from a large observational study (BRiTE)

Axel Grothey, Mary M. Sugrue, Eric Hedrick et al. · Journal of Clinical Oncology · 2007 · 55 citations

Medicine, Oncology, Pharmacotherapy +14

A Dose-Escalation Study of Venetoclax (ABT-199/GDC-0199) in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma

Sven de Vos, Lode J. Swinnen, M. Kozloff et al. · Blood · 2015 · 35 citations

Pharmacy, Oncology, Pharmacotherapy +12

Association of health-related quality of life with gender in patients with B-cell chronic lymphocytic leukemia

Chris L. Pashos, Christopher R. Flowers, Neil E. Kay et al. · Supportive Care in Cancer · 2013 · 33 citations

Medicine, Health Sciences, Oncology +11

Serious arterial thromboembolic events (sATE) in patients (pts) with metastatic colorectal cancer (mCRC) treated with bevacizumab (BV): Results from the BRiTE registry

Mary M. Sugrue, D. Purdie, Wei Dong et al. · Journal of Clinical Oncology · 2007 · 22 citations

Medicine, Oncology, Pharmacology +12